Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in a $3 Million Registered Direct Offering
February 24, 2016 – New York, NY – Press Release – Sichenzia Ross Friedman Ference LLP announced today that the Firm represented Amarantus BioScience Holdings, Inc. in a $3 million offering of the Company’s Series H Convertible Preferred Stock and Warrants to purchase common stock.
Chardan Capital Markets, LLC acted as sole placement agent for the transaction.
The securities were offered pursuant to an effective shelf registration statement.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey Fessler and Marcelle Balcombe.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $2.3 Million Public Offering of Common Stock of Sigma Labs, Inc. - August 3, 2019
- Sichenzia Ross Ference LLP Ranked as a Top Issuer Counsel for 2019 Q2 - July 24, 2019
- Sichenzia Ross Ference LLP Represents ThinkEquity in $1.35 Million Underwritten Public Offering of ADSs of Immuron Limited - July 23, 2019